The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Open accessAbstract
BACKGROUND: Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with ipilimumab-refractory metastatic melanoma. The use of nivolumab in previously untreated patients with advanced melanoma has not been tested in a phase 3 controlled study. METHODS: We randomly assigned 418 previously untreated patients who had metastatic melanoma without a BRAF mutation to receive nivolumab (at a dose of 3 mg per kilogram of body weight every 2 weeks and dacarbazine-matched placebo every 3 weeks) or dacarbazine (at a dose of 1000 mg per square meter of body-surface area every 3 weeks and nivolumab-matched placebo every 2 weeks). The primary end point was overall survival. RESULTS: At 1 year, the overall rate of survival was 72.9% (95% confidence interval [CI], 65.5 to 78.9) in the nivolumab group, as compared with 42.1% (95% CI, 33.0 to 50.9) in the dacarbazine group (hazard ratio for death, 0.42; 99.79% CI, 0.25 to 0.73; P<0.001). The median progression-free survival was 5.1 months in the nivolumab group versus 2.2 months in the dacarbazine group (hazard ratio for death or progression of disease, 0.43; 95% CI, 0.34 to 0.56; P<0.001). The objective response rate was 40.0% (95% CI, 33.3 to 47.0) in the nivolumab group versus 13.9% (95% CI, 9.5 to 19.4) in the dacarbazine group (odds ratio, 4.06; P<0.001). The survival benefit with nivolumab versus dacarbazine was observed across prespecified subgroups, including subgroups defined by status regarding the programmed death ligand 1 (PD-L1). Common adverse events associated with nivolumab included fatigue, pruritus, and nausea. Drug-related adverse events of grade 3 or 4 occurred in 11.7% of the patients treated with nivolumab and 17.6% of those treated with dacarbazine. CONCLUSIONS: Nivolumab was associated with significant improvements in overall survival and progression-free survival, as compared with dacarbazine, among previously untreated patients who had metastatic melanoma without a BRAF mutation. (Funded by Bristol-Myers Squibb; CheckMate 066 ClinicalTrials.gov number, NCT01721772.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“however responses to these therapies are often heterogeneous and not durable (1–3).”
From Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients (2018) · cites this paper as [3]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Treatment with immunotherapy targeting checkpoint inhibitors PD-1 or CTLA-4 significantly increases survival in patients with metastatic melanoma over other standards of care [1, 2]”
From Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients (2019) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While immune checkpoint inhibitors (ICIs) have greatly enhanced clinical outcomes across multiple cancer types,1, 2, 3”
From irAE-GPT: leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets (2026) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Nevertheless, the responses to ICI treatment have still been observed in those with low or undetectable levels of PD-L1 expression.9”
From The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti–Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC (2019) · cites this paper as [9]
In the citing paper
“Immune checkpoint blockade with monoclonal antibodies (mAbs) targeting programmed cell death protein 1 (PD-1) provides long-term clinical benefits to nearly 40% of patients with advanced melanoma (1–5).”
From Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients (2021) · cites this paper as [3]
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationNivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Self-citationHauschild, A., Grob, J., Демидов, Л. В., Jouary, T., Gutzmer, R., Millward, M. J., Rutkowski, P. L., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 3,050
Self-citationTopalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,205
Self-citationSurvival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1200/JCO.2013.51.4802 · DOI · Paper page
Cited by
Sorted by citations
Items 301–400 of 1,032
Immunotherapy of Melanoma: Facts and Hopes
Weiss, S. A., Wolchok, J. D., & Sznol, M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1550 · Cited by 284
Delivanis, D. A., Gustafson, M. P., Bornschlegl, S., Merten, M. M., Kottschade, L., Withers, S., Dietz, A. B., & Ryder, M. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00448 · Cited by 278
Immunotherapy in melanoma: Recent advances and future directions
Franklin, C., Livingstone, E., Roesch, A., Schilling, B., & Schadendorf, D. (2016) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2016.07.145 · Cited by 286
Self-citationThe Confluence of Sex Hormones and Aging on Immunity
Gubbels Bupp, M. R., Potluri, T., Fink, A. L., & Klein, S. L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01269 · Cited by 277
Foppen, M. H. G., Rozeman, E. A., van Wilpe, S., Postma, C., Snæbjörnsson, P., van Thienen, J. V., van Leerdam, M. E., van den Heuvel, M. M., Blank, C. U., van Dieren, J. M., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2017-000278 · Cited by 279
The genomic landscape of breast cancer and its interaction with host immunity
Luen, S. J., Virassamy, B., Savas, P. S., Salgado, R., & Loi, S. (2016) · The Breast · doi:10.1016/j.breast.2016.07.015 · Cited by 279
PD1 signal transduction pathways in T cells
Arasanz, H., Gato, M., Zuazo, M., Ibáñez-Vea, M., Breckpot, K., Kochan, G. T., & Escors, D. (2017) · Oncotarget · doi:10.18632/oncotarget.17232 · Cited by 287
Larkin, J., Chmielowski, B., Lao, C. D., Hodi, F. S., Sharfman, W. H., Weber, J. S., Suijkerbuijk, K. P. M., Azevedo, S. J., Li, H., Reshef, D. S., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0487 · Cited by 276
Immune system and melanoma biology: a balance between immunosurveillance and immune escape
Passarelli, A. M., Mannavola, F., Stucci, L. S., Tucci, M., & Silvestris, F. (2017) · Oncotarget · doi:10.18632/oncotarget.22190 · Cited by 287
Duffy, M. J., & Crown, J. P. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2019.303644 · Cited by 280
Molecular Mechanisms of Treatment Resistance in Glioblastoma
Ou, A. C., Yung, W. K. A., & Majd, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010351 · Cited by 283
Immunotherapy in Melanoma: Recent Advances and Future Directions
Knight, A., Karapetyan, L., & Kirkwood, J. M. (2023) · Cancers · doi:10.3390/cancers15041106 · Cited by 281
Zimmer, L., Vaübel, J., Mohr, P., Hauschild, A., Utikal, J. S., Simon, J. C., Garbe, C., Herbst, R. A., Enk, A., Kämpgen, E., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118564 · Cited by 270
Self-citationTokunaga, R., Sakamoto, Y., Nakagawa, S., Miyamoto, Y., Yoshida, N., Oki, E., Watanabe, M., & Baba, H. (2015) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000000458 · Cited by 268
The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
Brochez, L., Chevolet, I., & Krüse, V. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.011 · Cited by 271
Tracking the evolution of circulating exosomal‐PD‐L1 to monitor melanoma patients
Cordonnier, M., Nardin, C., Chanteloup, G., Dérangère, V., Algros, M., Arnould, L., Garrido, C., Aubin, F., & Gobbo, J. (2020) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2019.1710899 · Cited by 274
Lehrer, E. J., Peterson, J., Brown, P. D., Sheehan, J. P., Quiñones‐Hinojosa, A., Zaorsky, N. G., & Trifiletti, D. M. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.08.025 · Cited by 273
Parra, E. R., Uraoka, N., Jiang, M., Cook, P., Gibbons, D. L., Forget, M., Bernatchez, C., Haymaker, C., Wistuba, I. I., & Rodriguez‐Canales, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-13942-8 · Cited by 273
Immune checkpoint inhibitor-induced colitis: A comprehensive review
Som, A., Mandaliya, R. H., Alsaadi, D., Farshidpour, M., Charabaty, A., Malhotra, N., & Mattar, M. C. (2019) · World Journal of Clinical Cases · doi:10.12998/wjcc.v7.i4.405 · Cited by 271
Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors
Bajaj, G., Wang, X., Agrawal, S., Gupta, M., Roy, A., & Feng, Y. (2016) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12143 · Cited by 268
Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
Sibaud, V., Meyer, N., Lamant, L., Vigarios, É., Mazières, J., & Delord, J. P. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000290 · Cited by 269
Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients
Peters, B. A., Wilson, M., Moran, U., Pavlick, A., Izsak, A., Wechter, T., Weber, J. S., Osman, I., & Ahn, J. (2019) · Genome Medicine · doi:10.1186/s13073-019-0672-4 · Cited by 263
Spain, L. A., Walls, G., Julve, M., O’Meara, K., Schmid, T., Kalaitzaki, E., Turajlic, S., Gore, M. E., Rees, J. H., & Larkin, J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw558 · Cited by 264
Patterns of Response and Progression to Immunotherapy
Borcoman, É., Nandikolla, A. G., Long, G. V., Goel, S., & Tourneau, C. L. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200643 · Cited by 267
Self-citationChapman, P. B., Robert, C., Larkin, J., Haanen, J. B. A. G., Ribas, A., Hogg, D., Hamid, O., Ascierto, P. A., Testori, A., Lorigan, P. C., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx339 · Cited by 269
Self-citationImmunomodulatory spherical nucleic acids
Radovic‐Moreno, A. F., Chernyak, N., Mader, C. C., Nallagatla, S., Kang, R. S., Hao, L., Walker, D., Halo, T. L., Merkel, T. J., Rische, C. H., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502850112 · Cited by 260
Chukwueke, U. N., & Wen, P. Y. (2019) · CNS Oncology · doi:10.2217/cns-2018-0007 · Cited by 262
Checkpoint inhibitor immunotherapy in kidney cancer
Xu, W. V., Atkins, M. B., & McDermott, D. F. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0282-3 · Cited by 267
An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
Tan, S., Zhang, H., Chai, Y., Song, H., Tong, Z., Wang, Q., Qi, J., Wong, G., Zhu, X., Liu, W. J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14369 · Cited by 263
Cancer Immunotherapy, Part 3: Challenges and Future Trends.
Ventola, C. L. (2017) · PubMed Central · Cited by 257
CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy
Kagamu, H., Kitano, S., Yamaguchi, O., Yoshimura, K., Horimoto, K., Kitazawa, M., Fukui, K., Shiono, A., Mouri, A., Nishihara, F., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0574 · Cited by 256
Rogado, J., Sánchez-Torres, J. M., Romero-Laorden, N., Ballesteros, A. I., Pacheco-Barcia, V., Ramos-Leví, A., Arranz, R., Lorenzo, A., Gullón, P., Donnay, O., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.014 · Cited by 255
Systemic treatments for metastatic cutaneous melanoma
Pasquali, S., Hadjinicolaou, A. V., Chiarion‐Sileni, V., Rossi, C. R., & D, S. M. M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011123.pub2 · Cited by 258
Self-citationLaino, A. S., Woods, D. M., Vassallo, M., Qian, X., Tang, H., Wind‐Rotolo, M., & Weber, J. S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000842 · Cited by 259
Krupka, C., Kufer, P., Kischel, R., Zugmaier, G., Lichtenegger, F. S., Köhnke, T., Vick, B., Jeremias, I., Metzeler, K. H., Altmann, T., et al. (2015) · Leukemia · doi:10.1038/leu.2015.214 · Cited by 256
Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Giacomo, A. M. D., Mortier, L., Rutkowski, P. L., Hassel, J. C., McNeil, C. M., Kalinka‐Warzocha, E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00995 · Cited by 259
Self-citationRe, M. D., Marconcini, R., Pasquini, G., Rofi, E., Vivaldi, C., Bloise, F., Restante, G., Arrigoni, E., Caparello, C., Bianco, M. G., et al. (2018) · British Journal of Cancer · doi:10.1038/bjc.2018.9 · Cited by 256
Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events
González-Rodríguez, E., Rodríguez‐Abreu, D., & on behalf of the Spanish Group for Cancer Immuno-Biotherapy (GETICA) (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0509 · Cited by 254
Interferon-γ induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation
Yu, M., Peng, Z., Qin, M., Liu, Y., Wang, J., Zhang, C., Lin, J., Dong, T., Wang, L., Li, S., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.01.010 · Cited by 250
Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma
Cerezo, M., Guemiri, R., Druillennec, S., Girault, I., Malka-Mahieu, H., Shen, S., Allard, D., Martineau, S., Welsch, C., Agoussi, S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0217-1 · Cited by 257
Self-citationWeber, J., Gibney, G., Kudchadkar, R., Yu, B., Cheng, P., Martinez, A. J., Kroeger, J., Richards, A., McCormick, L., Moberg, V., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0193 · Cited by 248
Taube, J. M., Young, G. D., McMiller, T. L., Chen, S., Salas, J. T., Pritchard, T. S., Xu, H., Meeker, A. K., Fan, J., Cheadle, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0244 · Cited by 252
Zhao, X., Suryawanshi, S., Hruska, M. W., Feng, Y., Wang, X., Shen, J., Vezina, H. E., McHenry, M. B., Waxman, I. M., Achanta, A., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx235 · Cited by 250
Self-citationLong, G. V., Atkinson, V. G., Cebon, J. S., Jameson, M. B., Fitzharris, B. M., McNeil, C. M., Hill, A. G., Ribas, A., Atkins, M. B., Thompson, J. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30428-x · Cited by 248
Self-citationCardiotoxicity of immune checkpoint inhibitors
Varricchi, G., Galdiero, M. R., Marone, G., Criscuolo, G., Triassi, M., Bonaduce, D., Marone, G., & Tocchetti, C. G. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000247 · Cited by 247
Zimmer, L., Livingstone, E., Hassel, J. C., Fluck, M., Eigentler, T., Loquai, C., Haferkamp, S., Gutzmer, R., Meier, F. E., Mohr, P., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30417-7 · Cited by 251
Self-citationKhair, D. O., Bax, H. J., Mele, S., Crescioli, S., Pellizzari, G., Khiabany, A., Nakamura, M., Harris, R. J. C., French, E., Hoffmann, R. M., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00453 · Cited by 252
Molecular Markers and Targets in Melanoma
Teixidó, C., Castillo, P., Martínez-Vila, C., Arance, A. M., & Alós, L. (2021) · Cells · doi:10.3390/cells10092320 · Cited by 262
Self-citationTeng, F., Meng, X., Kong, L., & Yu, J. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.11.014 · Cited by 249
Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review
Khan, S., & Gerber, D. E. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.012 · Cited by 250
Paver, E. C., Cooper, W. A., Colebatch, A. J., Ferguson, P. M., Hill, S. K., Lum, T., Shin, J., O’Toole, S. A., Anderson, L. A., Scolyer, R. A., et al. (2020) · Pathology · doi:10.1016/j.pathol.2020.10.007 · Cited by 252
ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation
Hu, M., Zhou, M., Bao, X., Pan, D., Jiao, M., Liu, X., Li, F., & Li, C. (2020) · Journal of Clinical Investigation · doi:10.1172/jci139333 · Cited by 260
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer
Gong, B., Kiyotani, K., Sakata, S., Nagano, S., Kumehara, S., Baba, S., Besse, B., Yanagitani, N., Friboulet, L., Nishio, M., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20180870 · Cited by 248
Mechanisms of immune activation and regulation: lessons from melanoma
Kalaora, S., Nagler, A., Wargo, J. A., & Samuels, Y. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00442-9 · Cited by 252
Shi, V. J., Rodić, N., Gettinger, S. N., Leventhal, J. S., Neckman, J. P., Girardi, M., Bosenberg, M., & Choi, J. N. (2016) · JAMA Dermatology · doi:10.1001/jamadermatol.2016.2226 · Cited by 243
Vilain, R. E., Menzies, A. M., Wilmott, J. S., Kakavand, H., Madore, J., Guminski, A. D., Liniker, E., Kong, B. Y., Cooper, A. J., Howle, J. R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0698 · Cited by 247
Self-citationRadiation effects on antitumor immune responses: current perspectives and challenges
Walle, T., Monge, R. M., Cerwenka, A., Ajona, D., Melero, I., & Lecanda, F. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017742575 · Cited by 250
YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma
Kim, M. H., Kim, C. G., Kim, S.-K., Shin, S. J., Choe, E. A., Park, S.-H., Shin, E.-C., & Kim, J. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0320 · Cited by 241
Wang, X., Yang, X., Zhang, C., Wang, Y., Cheng, T., Duan, L., Tong, Z., Tan, S., Zhang, H., Saw, P. E., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1921445117 · Cited by 245
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Peyraud, F., & Italiano, A. (2020) · Cancers · doi:10.3390/cancers12061502 · Cited by 245
Development of PARP and immune-checkpoint inhibitor combinations
Stewart, R. A., Pilié, P. G., & Yap, T. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-2652 · Cited by 239
Ahmed, K. A., Stallworth, D. G., Kim, Y., Johnstone, P. A. S., Harrison, L. B., Caudell, J. J., Yu, H., Etame, A. B., Weber, J. S., & Gibney, G. T. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv622 · Cited by 240
Manegold, C., Dingemans, A. C., Gray, J. E., Nakagawa, K., Nicolson, M. C., Peters, S., Reck, M., Wu, Y.-L. L. C., Brustugun, O. T., Crinò, L., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.003 · Cited by 243
Bigot, F., Álvarez, E. C., Baldini, C., Hollebecque, A., Carmona‐Bayonas, A., Postel-Vinay, S. C., Angevin, E., Armand, J., Ribrag, V., Aspeslagh, S., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.027 · Cited by 246
Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents
Weber, J. S., Postow, M. A., Lao, C. D., & Schadendorf, D. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0055 · Cited by 244
Self-citationSantoni, M., Romagnoli, E., Saladino, T., Foghini, L., Guarino, S., Capponi, M., Giannini, M., Cognigni, P. D., Ferrara, G., & Battelli, N. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.10.007 · Cited by 241
A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1
Ngiow, S. F., Young, A., Jacquelot, N., Yamazaki, T., Enot, D., Zitvogel, L., & Smyth, M. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1082 · Cited by 237
Hong, X., Roh, W., Sullivan, R. J., Wong, K. H. K., Wittner, B. S., Guo, H., Dubash, T. D., Sade-Feldman, M., Wesley, B., Horwitz, E. P., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1500 · Cited by 243
Rodak, O., Peris‐Díaz, M. D., Olbromski, M., Podhorska‐Okołów, M., & Dzięgiel, P. (2021) · Cancers · doi:10.3390/cancers13184705 · Cited by 250
The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment
Pennock, G. K., & Chow, L. Q. M. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0422 · Cited by 241
The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy
Galle, P. R., Tovoli, F., Foerster, F., Wörns, M., Cucchetti, A., & Bolondi, L. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.007 · Cited by 238
Learning from clinical trials of neoadjuvant checkpoint blockade
Versluis, J. M., Long, G. V., & Blank, C. U. (2020) · Nature Medicine · doi:10.1038/s41591-020-0829-0 · Cited by 234
Self-citationDiverse types of dermatologic toxicities from immune checkpoint blockade therapy
Curry, J. L., Tetzlaff, M. T., Nagarajan, P., Drucker, C. R., Diab, A. K., Hymes, S. R., Duvic, M. A., Hwu, W., Wargo, J. A., Torres-Cabala, C. A., et al. (2016) · Journal of Cutaneous Pathology · doi:10.1111/cup.12858 · Cited by 235
Chen, Y., Zhang, Y. X., Lv, J.-W., Li, Y.-Q., Wang, Y., He, Q.-M., Yang, X.-J., Sun, Y. H., Mao, Y., Yun, J., et al. (2017) · Theranostics · doi:10.7150/thno.21471 · Cited by 234
Mutational Landscape and Sensitivity to Immune Checkpoint Blockers
Chabanon, R. M., Pedrero, M., Lefèbvre, C., Marabelle, A., Soria, J., & Postel-Vinay, S. C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0903 · Cited by 236
Trial Watch: Toll-like receptor agonists in cancer immunotherapy
Smith, M. M., García-Martínez, E., Pitter, M. R., Fucikova, J. P., Špíšek, R., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1526250 · Cited by 237
Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Amaral, T. M. S., Ottaviano, M., Arance, A. M., Blank, C. U., Chiarion‐Sileni, V., Donia, M., Dummer, R., Garbe, C., Gershenwald, J. E., Gogas, H. J., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.11.006 · Cited by 248
Self-citationTargeting immune cells for cancer therapy
Gun, S. Y., Lee, S. W. L., Sieow, J. L., & Wong, S. C. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101174 · Cited by 237
Jansen, Y. J. L., Rozeman, E. A., Mason, R., Goldinger, S. M., Foppen, M. H. G., Hoejberg, L., Schmidt, H., van Thienen, J. V., Haanen, J. B. A. G., Tiainen, L., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz110 · Cited by 229
Self-citationComprehensive Analysis of Cuproptosis-Related Genes in Immune Infiltration and Prognosis in Melanoma
Lv, H., Liu, X., Zeng, X., Liu, Y., Zhang, C.-J., Zhang, Q., & Xu, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.930041 · Cited by 233
CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
Callahan, M. K., Postow, M. A., & Wolchok, J. D. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2014.00385 · Cited by 236
Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
Agrawal, S., Feng, Y., Roy, A., Kollia, G. D., & Lestini, B. J. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0177-2 · Cited by 232
Rational design of anti-GITR-based combination immunotherapy
Zappasodi, R., Sirard, C. A., Li, Y., Budhu, S., Abu-Akeel, M., Liu, C., Yang, X., Zhong, H., Newman, W., Qi, J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0420-8 · Cited by 233
Chen, L., Satoh, T., Ryu, M., Chao, Y., Kato, K., Chung, H. C., Chen, J., Muro, K., Kang, W. K., Yeh, K., et al. (2019) · Gastric Cancer · doi:10.1007/s10120-019-01034-7 · Cited by 227
Long, G. V., Eroglu, Z., Infante, J. R., Patel, S. P., DAUD, A. I., Johnson, D. B., Gonzalez, R. C., Kefford, R. F., Hamid, O., Schuchter, L. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.1025 · Cited by 229
Self-citationda Silva, I. P., Ahmed, T., Reijers, I. L. M., Weppler, A. M., Warner, A. B., Patrinely, J. R., Serra-Bellver, P., Allayous, C., Mangana, J., Nguyen, K., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00097-8 · Cited by 229
Self-citationKawazoe, A., Kuwata, T., Kuboki, Y., Shitara, K., Nagatsuma, A. K., Aizawa, M., Yoshino, T., Doi, T., Ohtsu, A., & Ochiai, A. (2016) · Gastric Cancer · doi:10.1007/s10120-016-0631-3 · Cited by 229
Ben‐Ami, E., Barysauskas, C. M., Solomon, S., Tahlil, K., Malley, R., Hohos, M., Polson, K., Loucks, M., Severgnini, M., Patel, T., et al. (2017) · Cancer · doi:10.1002/cncr.30738 · Cited by 231
Immune checkpoint inhibitor‐related hypophysitis and endocrine dysfunction: clinical review
Joshi, M., Whitelaw, B., Palomar, M. T. P., Wu, Y., & Carroll, P. (2016) · Clinical Endocrinology · doi:10.1111/cen.13063 · Cited by 224
Larkin, J., Lao, C. D., Urba, W. J., McDermott, D. F., Horak, C., Jiang, J., & Wolchok, J. D. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1184 · Cited by 223
Self-citationRiesenberg, S., Groetchen, A., Siddaway, R., Bald, T., Reinhardt, J., Smorra, D., Sirokay, J. D., Renn, M., Phung, B., Aymans, P., et al. (2015) · Nature Communications · doi:10.1038/ncomms9755 · Cited by 238
Lencioni, R. A., Montal, R., Torres, F., Park, J., Decaens, T., Raoul, J., Kudo, M., Chang, C., Ríos, J., Boige, V., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.012 · Cited by 223
Tanizaki, J., Haratani, K., Hayashi, H., Chiba, Y., Nakamura, Y., Yonesaka, K., Kudo, K., Kaneda, H., Hasegawa, Y., Tanaka, K., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.10.030 · Cited by 227
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer
Liu, J. F., Herold, C. I., Gray, K. P., Penson, R. T., Horowitz, N. S., Konstantinopoulos, P. A., Castro, C. M., Hill, S. J., Curtis, J. D., Luo, W., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3343 · Cited by 225
Financial toxicity and implications for cancer care in the era of molecular and immune therapies
Tran, G. N., & Zafar, S. Y. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.03.28 · Cited by 225
Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
Grapin, M., Richard, C., Limagne, E., Boidot, R., Morgand, V., Bertaut, A., Dérangère, V., Laurent, P.-A., Thibaudin, M., Fumet, J.-D., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0634-9 · Cited by 230
Systemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma
Chamberlain, M. C., Baik, C. S., Gadi, V. K., Bhatia, S., & Chow, L. Q. M. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now197 · Cited by 224
In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer
Dubrot, J., Du, P. P., Lane-Reticker, S. K., Kessler, E. A., Muscato, A. J., Mehta, A., Freeman, S. S., Allen, P. M., Olander, K. E., Ockerman, K. M., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01315-x · Cited by 218
Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
Elias, R., Giobbie-Hurder, A., McCleary, N. J., Ott, P., Hodi, F. S., & Rahma, O. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0336-8 · Cited by 218
Dagar, G., Gupta, A., Masoodi, T., Nisar, S., Merhi, M., Hashem, S., Chauhan, R., Dagar, M., Mirza, S., Bagga, P., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04292-3 · Cited by 229
Metadata
- Authors
- Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., Savage, K. J., Hernberg, M. M., Lebbé, C., Charles, J., Mihalcioiu, C., Chiarion-Sileni, V., Mauch, C., Cognetti, F., Arance, A., Schmidt, H., Schadendorf, D., Gogas, H., Lundgren-Eriksson, L., Horak, C., Sharkey, B., Waxman, I. M., Atkinson, V., & Ascierto, P. A.
- Affiliations
- Inserm (FR)
- The University of Sydney (AU)
- Cabrini Hospital (AU)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- University of Siena (IT)
- Hôpital Claude Huriez (FR)
- University Hospital Heidelberg (DE)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- Royal Prince Alfred Hospital (AU)
- The authors' affiliations are listed in the Appendix.
- BC Cancer Agency (CA)
- Helsinki University Hospital (FI)
- Royal Victoria Hospital (CA)
- Centrum für Integrierte Onkologie (DE)
- Instituto Nazionale Tumori Regina Elena (IT)
- Hospital Clínic de Barcelona (ES)
- Aarhus University Hospital (DK)
- University of Duisburg-Essen (DE)
- National and Kapodistrian University of Athens (GR)
- Bristol-Myers Squibb (United States) (US)
- Greenslopes Private Hospital (AU)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- ORCID
- Robert, Caroline
- Long, Georgina V.
- Dutriaux, Caroline
- Maio, Michele
- Mortier, Laurent
- Hassel, Jessica C.
- Rutkowski, Piotr
- McNeil, Catriona
- Savage, Kerry J.
- Hernberg, Micaela M.
- Charles, Julie
- Mihalcioiu, Catalin
- Mauch, Cornelia
- Cognetti, Francesco
- Arance, Ana
- Schmidt, Henrik
- Schadendorf, Dirk
- Gogas, Helen
- Atkinson, Victoria
- Ascierto, Paolo A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-01-22
- Volume
- 372
- Issue
- 4
- Pages
- 320-330
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2128035403
- Semantic Scholar
- 6a8a53c7f9fd79ff959c6101698e58d58ff6123e
- Cited by
- 5,519
- References
- 25
- Citations by year
- 2026: 154 · 2025: 230 · 2024: 293 · 2023: 335 · 2022: 430 · 2021: 516 · 2020: 601 · 2019: 586 · 2018: 642 · 2017: 715 · 2016: 614 · 2015: 373
- FWCI
- 274.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- nivolumab, metastatic melanoma, BRAF wild-type melanoma, dacarbazine, immune checkpoint inhibitors, PD-1 inhibitors, overall survival, progression-free survival, objective response rate, PD-L1 expression, treatment-naive patients, adverse events, immunotherapy versus chemotherapy, subgroup analysis
- MeSH terms
- Nivolumab, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Dacarbazine, Double-Blind Method, Female, Humans, Male, Melanoma, Middle Aged, Survival Rate, Disease-Free Survival, Proto-Oncogene Proteins B-raf, Young Adult, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
